Pharmaceutical

Roche’s Columvi receives marketing approval in Europe

The European Commission has granted conditional marketing authorisation for Columvi to treat relapsed or refractory DLBCL in Europe.

Jul 11, 2023 - 20:00
Roche’s Columvi receives marketing approval in Europe
The European Commission has granted conditional marketing authorisation for Columvi to treat relapsed or refractory DLBCL in Europe.
Read the original article

Tags:

Previous Article

Israeli company bags $4.2m contract to develop cell therapy for radiation poisoning

Next Article

Iovance looks to advance its non-small cell lung cancer therapy

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: 4 ways the health care system should shift its thinking on AI, according to experts

STAT+: 4 ways the health care system should shift its t...

May 5, 2023

STAT+: ‘It’s like Groundhog Day’: The cancer drug shortage isn’t new — and neither are the solutions

STAT+: ‘It’s like Groundhog Day’: The cancer drug short...

Jun 28, 2023

Cristália signs licensing deal for Formosa’s APP13007

Cristália signs licensing deal for Formosa’s APP13007

Jan 29, 2024